Icon of the Instituts for Quality and Efficiency in Health Care

[A22-46] Dupilumab (severe asthma with type 2 inflammation) - Benefit assessment according to §35a Social Code Book V

Last updated 09.09.2022

Project no.:
A22-46

Commission:
Commission awarded on 19.04.2022 by the Federal Joint Committee (GBA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Children's and adolescents' health

Indication:

Children between 6 and 11 years of age with severe asthma with type 2 inflammation which is not properly controlled despite moderate-to-high-dose inhaled corticosteroids (ICS) plus one further drug as maintenance treatment.

Result of dossier assessment:

Added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

The current version 1.1 of the dossier assessment replaces version 1.0 published on Jul 15, 2022.

Project no. Title Status
A17-63 Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V Commission completed
A19-74 Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V Commission completed
A19-75 Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V Commission completed
A19-96 Dupilumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V Commission completed
A20-123 Dupilumab (atopic dermatitis in children) - Benefit assessment according to §35a Social Code Book V Commission completed
A23-24 Dupilumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V Commission completed
A23-25 Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V Commission completed
A23-23 Dupilumab (eosinophilic oesophagitis) – Benefit assessment according to §35a Social Code Book V Commission completed
A26-49 Dupilumab (chronic spontaneous urticaria in children >= 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V Commission completed
A26-50 Dupilumab (chronic spontaneous urticaria in adults and adolescents 12 years and above) – Benefit assessment according to §35a Commission completed
A24-117 Dupilumab (eosinophilic oesophagitis, 1 to 11 years) – Benefit assessment according to §35a Social Code Book V Commission completed
A24-79 Dupilumab (COPD) – Benefit assessment according to §35a Social Code Book V Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page